Endocrine Abstracts

Introduction: The purpose of this study was to evaluate and compare disease outcomes in patients with acromegaly receiving first-line and second-line (after transphenoidal surgery) somatostatin analogs (SSA) treatment.Methods: The study involved retrospective data collection from charts of 49 patients with acromegaly who were consulted by an endocrinologist in Vilnius University Hospital Santariskiu klinikos between 2007 and 2013.R...

Introduction: The purpose of this study was to characterize management and outcomes of patients with acromegaly seen in single centre in Lithuania.Methods: The study involved retrospective data collection from charts of 44 patients who were admitted to the centre between 2007 and 2012.Results: All cases except one were caused by pituitary adenomas (61.4% macroadenomas, and 29.5% microadenomas). The most common co-morbidities were n...

Introduction: The purpose of this study was to evaluate effectiveness of somatostatin analog (SSA) treatment in patients with acromegaly.Methods: The study involved retrospective data collection from charts of 29 patients with acromegaly who received medical therapy at Vilnius University Hospital Santariskiu klinikos in 2016.Results: Patient population consisted of 10 males (34.5%) and 19 females (65.5%), mean age 58±26 years....

Introduction: The purpose of this study was to evaluate treatment options and effectiveness in patients with acromegaly.Methods: The study involved retrospective data collection from charts of 75 patients with acromegaly who was treated at Vilnius University Hospital Santaros klinikos.Results: Patient population consisted of 21 males (28%) and 54 females (72%), mean age at diagnosis 52 ± 13 years. In most of the cases, macroad...

Background: The prevalence of pituitary adenomas (PAs) is increasing as the development of imaging techniques. The objective of this study is to assess the clinical and morphological features of non-functioning, prolactin, and grown-hormone secreting pituitary adenomas and to analyze the accompanying diseases of each condition.Methods: A retrospective analysis of the clinical records of patients with non-functioning (NFPA), prolactin (PRL+) or grown horm...

Background: Dopamine agonists (DAs) are the primary treatment for both microprolactinomas and macroprolactinomas. Two medications are FDA approved for the medical treatment of prolactinomas: cabergoline and bromocriptine. Although bromocriptine is deemed a secondary option after cabergoline, its lower cost may be a consideration for some patients. The purpose of this study is to analyze patients treated with different DAs during 12 months period and to identify the unchangeabl...